PepGen (PEPG) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on June 4, 2025, with voting on director elections and auditor ratification.
Stockholders of record as of April 8, 2025, are eligible to vote; 32,720,943 shares of common stock are outstanding.
Proxy materials are distributed primarily via the Internet to reduce costs and environmental impact.
Voting matters and shareholder proposals
Stockholders will vote on electing three Class III directors for three-year terms and ratifying KPMG LLP as the independent auditor for 2025.
The board recommends voting FOR all director nominees and FOR auditor ratification.
Stockholders may submit proposals for the 2026 meeting by December 26, 2025, for proxy inclusion.
Board of directors and corporate governance
The board is divided into three staggered classes; recent changes increased its size to eight members.
Board diversity is emphasized, with a mix of gender, backgrounds, and expertise.
All directors except the CEO are independent; the board separates the chair and CEO roles.
Committees include audit, compensation, and nominating/governance, all meeting Nasdaq and SEC requirements.
Annual board and committee self-evaluations are conducted, often with third-party facilitation.
Latest events from PepGen
- Record splicing improvements and robust safety data drive global DM1 trial progress.PEPG
Leerink Global Healthcare Conference 202610 Mar 2026 - PGN-EDODM1 shows best-in-class splicing correction and strong safety in DM1 trials.PEPG
Company presentation4 Mar 2026 - PGN-EDODM1 delivers best-in-class splicing correction and strong safety in DM1 trials.PEPG
corporate presentation4 Mar 2026 - Advancing DM1 clinical program with strong cash position and key data readouts expected in 2026.PEPG
Q4 20254 Mar 2026 - Best-in-class exon skipping and dystrophin gains with strong safety at 5 mg/kg.PEPG
Corporate Presentation2 Feb 2026 - DM1 and DMD programs show strong efficacy and safety, with key data readouts expected this year.PEPG
Virtual CNS Forum26 Dec 2025 - DM1 and DMD programs show strong efficacy and safety, with pivotal data expected soon.PEPG
Leerink’s Global Healthcare Conference 202526 Dec 2025 - Registering up to $250M in securities to fund R&D and pipeline for neuromuscular therapies.PEPG
Registration Filing16 Dec 2025 - Stockholders will vote on director elections and auditor ratification at the June 2025 virtual meeting.PEPG
Proxy Filing2 Dec 2025